Biomarkers of Immunosuppressant Therapy Resistance in Primary FSGS
Main study | Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis: Phase II Clinical Trial |
---|---|
Contact name | Robert Woronieki, MD |
Contact phone | 718-655-1120 |
Contact email | rworonie@aecom.yu.edu |